Navigation Links
The Market for Pancreatic Cancer Therapies Will Nearly Double to $1.3 Billion in 2022, Fueled by the Entry of Three Novel Agents
Date:5/7/2013

BURLINGTON, Mass., May 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents—Celgene/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.

"There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX's efficacy," said Decision Resources Analyst Orestis Mavroudis-Chocholis Ph.D. "FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed to only a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status.  Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer."

The report also finds that physicians are excited by the prospect of SPARC stromal overexpression as a predictive biomarker for response to Abraxane and hope that this could signal the start of a personalized approach to the treatment of pancreatic cancer.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CPhI China 2013 Increases Customer Content Services and Expands Thanks to a Double Digit Pharma Industry Growth Rate and a Burgeoning Generics Market
2. Hill-Rom Receives FDA 510(k) Clearance to Market MetaNeb 4.0 Airway Clearance System
3. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
4. Positron And Biologics Modular Enter Into Co-Marketing Agreement
5. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
6. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
7. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
8. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
9. Thorne Research and YouCare Pharmaceutical Group Announce Joint Venture Deal to Market Nutritional Supplements in China
10. Pharmacy Automation Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
11. Pharmaceutical Market: Finland, Ireland, Denmark, Belgium, Cuba, Austria & Norway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... 29, 2017 In a move that promises ... compliance for veterinary practices of all sizes, Cubex LLC ... that makes TITAN,s expertise in physical security, drug diversion ... clients nationally. ... controlled substances is at risk today," said TITAN founder ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... Hill, CT (PRWEB) , ... September 19, 2017 ... ... support, today announced the winners of the Entrepreneur Innovation Awards (EIA), held this ... all of whom are Connecticut-based companies and entrepreneurs, presented their innovative project ideas ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a new ... we’re born, Nature gives us a full supply of melanin – in the back ... this natural glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown ...
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day ... best practices for third party administrators (TPAs) related to health plan management and ...
Breaking Medicine News(10 mins):